Latest European Expansion News

Little Green Pharma reported a robust June 2025 quarter with record cash receipts and expanding European footprint, highlighted by a new production capacity in Denmark and the launch of its CherryCo brand in Germany.

Osteopore Limited has gained Swiss market approval for its 3D-printed bioresorbable implants under the EU Medical Device Regulation, completing its European product portfolio and strengthening its partnership with Zimmer Biomet.

Vection Technologies has landed a $4 million contract with Italy’s Omniacom Group to deploy its AI-integrated extended reality solutions across multiple sectors, marking a milestone in its European expansion.

Provaris Energy has raised $1.08 million through a share placement to accelerate its hydrogen and carbon dioxide storage and transport infrastructure development in Europe, including a prototype hydrogen tank program in Norway.

Sprintex secures a key deposit from Mest Water to develop new compressors for mobile manure processing systems, leveraging a Dutch government subsidy aimed at thousands of small farms.

Little Green Pharma Ltd has reported a robust turnaround for FY2025, posting a $3.3 million profit after tax on revenues up 43%, driven by strong growth in Australia and Europe and strategic acquisitions.

Sprintex has commissioned an upgraded manure processing system with Mest Water, setting the stage for a major trial at Van Drie Group farms that could unlock A$8.4 million in revenue. The company is also expanding its market reach with a new mobile system targeting smaller farms amid tightening EU ammonia regulations.

Wellnex Life Limited reports a robust 46% revenue increase and successful AIM listing, setting the stage for UK and European expansion.

Redivium Limited has launched its Trading Division and secured key agreements as it pushes forward with European battery recycling projects, though funding challenges remain.

Little Green Pharma reported a robust 40% revenue increase for FY25, driven by strong European sales and the strategic acquisition of Health House. The company also advanced clinical research and secured new therapy funding, positioning itself for continued growth.

Medical Developments International reported a robust Q3 FY25 with $8.9 million revenue and $1.7 million operating cashflow, driven by strong Penthrox demand and pricing. New distribution agreements in France and Switzerland position the company for further European expansion.

Adslot Ltd reports a robust Q2 FY25 with significant contract wins for its StoreFront platform and a 43% quarter-on-quarter increase in monetised transaction value, despite ongoing challenges in the Australian market.